top of page

Free Biopharma Daily Stock Updates - 04/12/22

$XBI $87.15 | -.019%

 

Covid Updates

$



Pipeline Updates

$TPTX +0.6% Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study source


$PSNL 0.0% Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene. source


$CYDY -5.4% CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”. source


$OCGN -3.8% Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152). source


$CLSN -1.7% Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress. source


$PSNL 0.0% Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform. source


$DARE -2.1% Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1. source


$AQST 0.0% Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film. source


$CLBS -0.7% Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease. source


$COCP +1.0% Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral. source


$KDNY 0.0% Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias. source


$UBX -1.0% UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema. source


$CDXS -0.2% Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis. source


$MTEM -3.5% Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach. source


$ATNM +24.0% Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa. source


$VTGN +4.5% VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B. source


$AGLE -8.2% Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency. source


$MYOV -25.1% Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis. source



Business Updates

$AFMD -9.0% Affimed Announces Proposed Public Offering of Common Shares source


$PROG -5.5% Progenity to Become Biora Therapeutics as it Completes Transformation. source


 

Posted by FS/JM

0 comments
bottom of page